.webp)
Engineers develop lipid nanoparticles that could transform personalized medicine and gene therapy.
Researchers at the University of Pennsylvania have developed a new approach toward mRNA therapy using siloxane nanoparticles, building a groundbreaking leap forward in targeted drug delivery. By modifying the chemical structure of lipid nanoparticles, originally used for COVID-19 vaccines, scientists created siloxane-incorporating lipid nanoparticles (SiLNPs) that showed an unique capacity for delivering mRNA into target organs such as the liver, lung, or spleen.
The key innovation was siloxane, a silicon- and oxygen-based material that is generally thought to be stable and nontoxic. It needed to undergo subtle chemical modifications, such as swapping an amide for an ester, to get to a 90% success rate at hitting lung tissue. By comparison, these methods have revolutionized conventional ones in which the LNPs tend to conglomerate in the liver.
Such a research thus has the potential application of SiLNPs in regenerative medicine and gene editing, especially in treatments associated with blood vessels' conditions. Their properties also facilitate a sixfold increase in mRNA delivery efficiency versus present LNP standards. Therefore, advancement in personalized medicine may be able to provide more effective treatments for diseases, opening new avenues for clinical applications of mRNA therapies in medicine.
.webp)
